Aug 8, 2024, 13:30
MARIPOSA for EGFR-mutant lung cancer – EGFR Positive UK
EGFR Positive UK shared a post on X:
”Interesting discussion re future of osimertinib following the MARIPOSA study, which ‘shows a significant improvement in progression-free survival with amivantamab plus lazertinib in EGFR-mutant lung cancer, potentially setting a new standard of care.”
Source: EGFR Positive UK/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14